<DOC>
	<DOC>NCT02959177</DOC>
	<brief_summary>The main purpose of this study is to determine the efficacy of the study drug Galcanezumab in Japanese participants with episodic migraine.</brief_summary>
	<brief_title>A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Have a diagnosis of migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)3 beta guidelines (1.1 or 1.2) (ICHD3 2013), with a history of migraine headaches of at least 1 year prior to screening, and migraine onset prior to age 50. Are currently enrolled in or have participated within the last 30 days or within 5 halflives (whichever is longer) in a clinical trial involving an investigational product. Current use or prior exposure to Galcanezumab or other antibodies to CGRP or its receptor. Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to Galcanezumab and the excipients in the investigational product. History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilartype migraine) defined by IHS ICHD3 beta.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>prevention</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>headache</keyword>
</DOC>